IRWD · Ironwood Pharmaceuticals Inc

$4.31 +0.23 (+5.64%) At close · Aug 14

Market Cap

$712.18M

165.24M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date	Headline
2026-07-14	Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
2026-05-28	Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
2026-05-27	FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
2026-05-07	Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
2026-05-04	Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
2026-04-30	Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
2026-04-23	Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
2026-03-04	Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
2026-02-25	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
2026-02-18	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
2026-01-02	Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
2025-11-10	Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
2025-08-07	Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
2025-05-07	Ironwood Pharmaceuticals Reports First Quarter 2025 Results
2025-04-30	Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
2025-04-25	Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
2025-04-22	Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
2025-04-14	Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
2025-03-27	Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
2025-02-27	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
2025-02-20	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
2025-01-29	Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
2024-11-26	Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
2024-11-13	Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
2024-11-07	Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

Past events

Date	Event	Type
2026-06-04	Jefferies Global Healthcare Conference	Conference
2026-05-07	Ironwood Pharmaceuticals Q1 2026 Investor Update Conference Call	Earnings call
2026-03-11	The Citizens Life Sciences Conference	Conference
2026-02-25	Ironwood Pharmaceuticals Q4 and Full Year 2025 Investor Update Conference Call	Earnings call
2025-05-07	The Citizens Life Sciences Conference	Conference
2025-02-27	Ironwood Pharmaceuticals Q4 and Full Year 2024 Investor Update Conference Call	Earnings call
2025-01-29	Ironwood Pharmaceuticals Corporate Update	Event
2024-12-04	Piper Sandler 36th Annual Healthcare Conference	Conference
2024-11-20	Jefferies London Healthcare Conference	Conference
2024-11-07	Ironwood Pharmaceuticals Q3 2024 Investor Update Conference Call	Earnings call
2024-10-29	ACG Oral Presentation of STARS Subgroup Analyses by Baseline Demographics and SBS Disease Characteristics	Presentation
2024-09-05	2024 Wells Fargo Healthcare Conference	Conference
2024-08-08	Ironwood Pharmaceuticals Q2 2024 Investor Update Conference Call	Earnings call
2024-06-06	Jefferies Global Healthcare Conference	Conference
2024-05-21	Ironwood Late-Breaker Oral Presentation at Digestive Disease Week®	Presentation
2024-05-13	The Citizens JMP Life Sciences Conference	Conference
2024-05-09	Ironwood Pharmaceuticals Q1 2024 Investor Update Conference Call	Earnings call
2024-02-29	STARS Phase 3 Positive Topline Results Conference Call	Earnings call
2024-02-15	Ironwood Pharmaceuticals Q4 and Full Year 2023 Investor Update Conference Call	Earnings call
2024-01-10	42nd Annual J.P. Morgan Healthcare Conference	Conference
2023-11-29	Piper Sandler 35th Annual Healthcare Conference	Conference
2023-11-09	Ironwood Pharmaceuticals Q3 2023 Investor Update Conference Call	Earnings call
2023-08-08	Ironwood Pharmaceuticals Q2 2023 Investor Update Conference Call	Earnings call
2023-05-22	Ironwood Announces Agreement to Acquire VectivBio	Event
2023-05-16	The JMP Securities Life Sciences Conference	Conference

Source: https://investor.ironwoodpharma.com/home/default.aspx

Key facts CIK 1446847 CUSIP 46333X108 13F (30d) 208 filings 201 filers Visit website Investor relations